Evidence map›Paper›PMID 28766273›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2017

Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding.

Rhonda Voskuhl, Callene Momtazee

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01466114 (A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis), which is not on this map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01466114 phase2unknown statusnot on this map

A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.

TypeinterventionalSponsorUniversity of California, Los AngelesRan2011 to 2022Enrolled64ConditionsRelapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple SclerosisArmsestriol, Placebo, Norethindrone, Progestin Placebo
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.Laboratory investigation; a journal of technical methods and pathology · 2023
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rhonda VoskuhlMultiple Sclerosis Program, UCLA Department of Neurology, David Geffen School of Medicine, University of Los Angeles, Los Angeles, CA, 90095, USA. rvoskuhl@mednet.ucla.edu.
Callene MomtazeeMultiple Sclerosis Program, UCLA Department of Neurology, David Geffen School of Medicine, University of Los Angeles, Los Angeles, CA, 90095, USA.
University of California, Los Angeles · US

Funding

Parental imprinting of the X chromosome: effects on neurodegenerationR01NS096748 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2016 to 2020
$1.9M
California Community Foundation BAPP-15-118094Conrad N. Hilton Foundation 20150232National Institute of Neurological Disorders and Stroke RO1NS096748NINDS NIH HHS R01 NS096748
6 · The paper itself

Abstract

Multiple sclerosis (MS) commonly affects women in childbearing years making pregnancy issues important for patients with MS and their families. Pregnancy is a naturally occurring disease modifier of MS associated with a 70% reduction in relapse rates in the third trimester. This relapse rate reduction during the last trimester is roughly equal to the most effective disease-modifying treatments for MS. Given this efficacy, various pregnancy factors have been tested to determine which play a part in pregnancy's protection, and some have been translated to completed and ongoing phase II clinical trials. In contrast to protective effects during pregnancy, the postpartum period entails increased relapse risk, which may be due to either abrupt removal of protective pregnancy factors after delivery or to unique deleterious factors inherent to the postpartum period. The effect of breastfeeding on MS remains unclear. The best predictor for whether a patient will have a postpartum relapse is the incidence of her having active relapsing MS prior to pregnancy. The medical management of MS during pregnancy and the postpartum period is challenging given the risks of medication exposure to the fetus in utero and to the infant through breast milk. This review will focus on clinical aspects of pregnancy, including the effects of pregnancy on MS disease activity, as well as the medical management of MS during pregnancy and postpartum.

Indexed as

Breast FeedingPregnancy ComplicationsAnimalsClinical Trials as TopicFemaleHumansMultiple SclerosisPostpartum PeriodPregnancyPregnancy Trimester, ThirdRecurrenceBreastfeedingDisease-modifying therapiesEstriolEstrogenMultiple sclerosisPregnancy

Identifiers

PMID28766273
PMCPMC5722767
OpenAlexW2741378031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.